Jennifer Wu

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. ncbi Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer
    Jennifer Wu
    Divisions of Hematology and Medical Oncology, Department of Medicine, NYU Cancer Institute, NYU School of Medicine, 550 First Ave, BCD 556, New York, NY 1006, USA
    Anticancer Res 32:939-45. 2012
  2. ncbi Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
    Jennifer Wu
    Department of Medical Oncology, NYU School of Medicine, New York, NY, USA
    Invest New Drugs 28:670-6. 2010
  3. ncbi Targeting insulin-like growth factor axis in hepatocellular carcinoma
    Jennifer Wu
    Division of Hematology and Medical Oncology, NYU Cancer Institute, NYU School of Medicine, New York, NY 10016, USA
    J Hematol Oncol 4:30. 2011
  4. ncbi Targeted therapy: its status and promise in selected solid tumors. Part II: Impact on selected tumor subsets, and areas of evolving integration
    Sasha O Joseph
    Division of Hematology and Oncology, New York University NYU School of Medicine, New York, New York 10016, USA
    Oncology (Williston Park) 26:1021-30, 1035. 2012
  5. ncbi Targeted therapy: its status and promise in selected solid tumors part I: areas of major impact
    Jennifer Wu
    Division of Hematology and Oncology, New York University NYU School of Medicine, New York, New York 10016, USA
    Oncology (Williston Park) 26:936-43. 2012
  6. ncbi Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
    Anna C Pavlick
    New York University School of Medicine, New York University Cancer Institute, New York, NY, USA
    Cancer Chemother Pharmacol 64:803-10. 2009
  7. ncbi Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin
    Ping Gu
    Department of Hematology and Medical Oncology, NYU Cancer Institute, New York, NY 10016, USA
    Int J Hepatol 2012:131659. 2012

Detail Information

Publications7

  1. ncbi Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancer
    Jennifer Wu
    Divisions of Hematology and Medical Oncology, Department of Medicine, NYU Cancer Institute, NYU School of Medicine, 550 First Ave, BCD 556, New York, NY 1006, USA
    Anticancer Res 32:939-45. 2012
    ..We explored its tolerance and preliminary efficacy when given together with cisplatin in a phase I/II study preferentially enrolling gastric cancer patients...
  2. ncbi Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
    Jennifer Wu
    Department of Medical Oncology, NYU School of Medicine, New York, NY, USA
    Invest New Drugs 28:670-6. 2010
    ..Darinaparsin is a novel organic arsenic that reaches higher intracellular concentration with decreased toxicity compared to inorganic arsenic. We conducted a multi-center phase II study with darinaparsin in patients with advanced HCC...
  3. ncbi Targeting insulin-like growth factor axis in hepatocellular carcinoma
    Jennifer Wu
    Division of Hematology and Medical Oncology, NYU Cancer Institute, NYU School of Medicine, New York, NY 10016, USA
    J Hematol Oncol 4:30. 2011
    ..IGF axis is increasingly recognized as one of the most relevant pathways in HCC and agents targeting this axis can potentially play an important role in the treatment of HCC...
  4. ncbi Targeted therapy: its status and promise in selected solid tumors. Part II: Impact on selected tumor subsets, and areas of evolving integration
    Sasha O Joseph
    Division of Hematology and Oncology, New York University NYU School of Medicine, New York, New York 10016, USA
    Oncology (Williston Park) 26:1021-30, 1035. 2012
    ..Taken together, these two types of advance illustrate the remarkable overall effect of modern cancer therapeutics' focus on tumor biology and tumor immunology...
  5. ncbi Targeted therapy: its status and promise in selected solid tumors part I: areas of major impact
    Jennifer Wu
    Division of Hematology and Oncology, New York University NYU School of Medicine, New York, New York 10016, USA
    Oncology (Williston Park) 26:936-43. 2012
    ....
  6. ncbi Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
    Anna C Pavlick
    New York University School of Medicine, New York University Cancer Institute, New York, NY, USA
    Cancer Chemother Pharmacol 64:803-10. 2009
    ..We designed a phase I study to achieve tolerable doses and schedules of bryo and cisplatin in combination and in this sequence...
  7. ncbi Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin
    Ping Gu
    Department of Hematology and Medical Oncology, NYU Cancer Institute, New York, NY 10016, USA
    Int J Hepatol 2012:131659. 2012
    ..Future studies will likely further define the role of these agents in patients with carcinoid liver metastasis and pancreatic NET liver metastasis...